Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.55 |
| ▸ | TOP1 | P11387 | 4/20 | 0.54 |
| ▸ | CYCS | P99999 | 3/20 | 0.52 |
| ▸ | TERT | O14746 | 4/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 4/20 | 0.44 |
| ▸ | MMP9 | P14780 | 4/20 | 0.44 |
| ▸ | MMP8 | P22894 | 4/20 | 0.44 |
| ▸ | MMP13 | P45452 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29405657 | 0.97 | ENPP2 (0.57) | ENPP2TOP1CYCSTERTABCG2 | |
| SCHEMBL11327076 | 0.97 | ENPP2 (0.57) | ENPP2TOP1CYCSTERTABCG2 | |
| SCHEMBL30201625 | 0.95 | ENPP2 (0.56) | ENPP2TOP1CYCSTERTABCG2 | |
| SCHEMBL13249184 | 0.95 | CYCS (0.56) | ENPP2TOP1CYCSTERTABCG2 | |
| SCHEMBL31154457 | 0.91 | TOP1 (0.55) | ENPP2TOP1CYCSTERTMMP2 | |
| SCHEMBL10587131 | 0.91 | TOP1 (0.55) | ENPP2TOP1CYCSTERTMMP2 | |
| SCHEMBL15134783 | 0.91 | TOP1 (0.55) | ENPP2TOP1CYCSTERTMMP2 | |
| SCHEMBL30556440 | 0.91 | TOP1 (0.55) | ENPP2TOP1CYCSTERTMMP2 | |
| SCHEMBL8355904 | 0.91 | TOP1 (0.55) | ENPP2TOP1CYCSTERTMMP2 | |
| SCHEMBL15134782 | 0.91 | TOP1 (0.55) | ENPP2TOP1CYCSTERTMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11629160-B2 | Corrole-based frameworks and methods of use thereof | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-04-18 | — | — | US | disclosed |
| US-11529332-B2 | Corroles for treating poxvirus infection | UNIVERSITE DE BOURGOGNE (FR) | 2022-12-20 | — | — | US | disclosed |
| US-11529332-B2 | Corroles for treating poxvirus infection | UNIVERSITE DE BOURGOGNE (FR) | 2022-12-20 | — | — | US | disclosed |
| US-20220267361-A1 | CORROLE-BASED FRAMEWORKS AND METHODS OF USE THEREOF | UNIVERSITY OF SOUTH FLORIDA | 2022-08-25 | — | — | US | disclosed |
| US-11395816-B2 | Corroles for treating human cytomegalovirus infections | UNIVERSITE DE BOURGOGNE (FR) | 2022-07-26 | — | — | US | disclosed |
| US-20210369671-A1 | CORROLES FOR TREATING HUMAN CYTOMEGALOVIRUS INFECTIONS | UNIVERSITE DE BOURGOGNE (FR) | 2021-12-02 | — | — | US | disclosed |
| US-20210169853-A1 | CORROLES FOR TREATING POXVIRUS INFECTION | UNIVERSITE DE BOURGOGNE (FR) | 2021-06-10 | — | — | US | disclosed |
| WO-2021035010-A1 | CORROLE-BASED FRAMEWORKS AND METHODS OF USE THEREOF | MA SHENGQIAN (US) | 2021-02-25 | — | — | WO | disclosed |
| EP-3716971-A1 | CORROLES FOR TREATING POXVIRUS INFECTION | Université de Bourgogne (FR) | 2020-10-07 | — | — | EP | disclosed |
| EP-3716970-A1 | CORROLES FOR TREATING HUMAN CYTOMEGALOVIRUS INFECTIONS | Université de Bourgogne (FR) | 2020-10-07 | — | — | EP | disclosed |
| EP-3492078-A1 | CORROLES FOR TREATING HUMAN CYTOMEGALOVIRUS INFECTIONS | Université de Bourgogne (FR) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492079-A1 | CORROLES FOR TREATING POXVIRUS INFECTION | Université de Bourgogne (FR) | 2019-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11529332-B2 | Corroles for treating poxvirus infection | VAC14, PPOX, GPX4 | ENPP2 299/4885TOP1 145/4885CYCS 184/4885 |
| US-11395816-B2 | Corroles for treating human cytomegalovirus infections | MGMT, RPL35, RPL5 | ENPP2 859/4885TOP1 53/4885CYCS 376/4885 |
| US-20210169853-A1 | CORROLES FOR TREATING POXVIRUS INFECTION | VAC14, PPOX, GPX4 | ENPP2 299/4885TOP1 145/4885CYCS 184/4885 |
| US-11629160-B2 | Corrole-based frameworks and methods of use thereof | CA13, CA12, ERCC4 | ENPP2 3724/4885TOP1 1379/4885CYCS 67/4885 |
| US-20210369671-A1 | CORROLES FOR TREATING HUMAN CYTOMEGALOVIRUS INFECTIONS | MGMT, RPL35, RPL5 | ENPP2 859/4885TOP1 53/4885CYCS 376/4885 |
| US-20220267361-A1 | CORROLE-BASED FRAMEWORKS AND METHODS OF USE THEREOF | CA13, CA12, ERCC4 | ENPP2 3724/4885TOP1 1379/4885CYCS 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.